Breaking News, Promotions & Moves

Ardena Names Paul Edwards Chief People Officer

Edwards joins Ardena after 16 years at Catalent.

Author Image

By: Patrick Lavery

Content Marketing Editor

Ardena has appointed Paul Edwards as its new Chief People Officer (CPO). Edwards comes to Ardena following 16 years at Catalent Pharma Solutions, where he was most recently Vice President, Human Resources.

Edwards’ appointment adds to two other personnel moves Ardena announced in late 2025. In November, the company named Dipesh Patel Chief Quality Officer and Peter Rose Chief Information Officer.

Edwards CPO Duties and Responsibilities

Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO, says Edwards will lead the company’s “global people strategy.”

More specifically, he will be tasked with strengthening capabilities both organization-wide and in a leadership context. Growing Ardena internationally, the company says, involves building a high-performance culture and ensuring support for productivity, speed, and scalability.

Ardena will ask Edwards to clarify accountability and develop talent and engagement frameworks, using his experience leading international HR teams.

Ardena CEO Jeremie Trochu said Edwards will play a “key role” in evolving the company in line with strategic ambitions.

“His track record leading global HR organizations within the biopharma services sector makes him a very strong addition,” Trochu said. “As Ardena continues to expand its capabilities and footprint internationally, investing in our people, leadership and culture is essential.”

“Ardena has a clear strategy and very strong scientific and technical foundations,” Edwards said. “I look forward to working with my new colleagues across the organization to further develop our leadership capability.”

Other Ardena News

Earlier in 2026, Ardena completed the divestment of its active pharmaceutical ingredient (API) site in Södertälje, Sweden, to Nanologica AB.

Ardena said at the time it would continue supporting customers with its integrated development approach. Prior to the deal, Ardena and Nanologica shared a long-standing relationship; Ardena has now becomes a shareholder in Nanologica.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters